Mall PA
RETA NOT FOR HUMANS CHECK BEFORE YOU COMPETE
File 09 · investigational triple hormone receptor agonist (GIP, GLP-1 and glucagon receptors)

Retatrutide

Also called: LY3437943, reta, GLP-3 (slang), triple agonist

Not named. Gray areaModerate

Retatrutide is an investigational once-weekly injectable from Eli Lilly that activates three hormone receptors (GIP, GLP-1 and glucagon), one more than tirzepatide. It is in phase 3 trials for obesity and related conditions and is not approved anywhere.

Why the gym talks about it

Its trial weight-loss numbers are the largest reported for any obesity drug so far, so it has a reputation as the next-generation cutting drug. Gray-market 'research' versions circulate well ahead of any approval.

What the research actually found

  • human randomized trial (phase 2)In a 48-week phase 2 trial of 338 adults with obesity, the highest dose group lost an average of 24.2% of body weight versus 2.1% on placebo; side effects were mainly dose-related gastrointestinal effects, and heart rate rose in a dose-dependent way. Source
  • human randomized trial (phase 3)In the 80-week phase 3 TRIUMPH-1 trial (2,339 adults with obesity, published Sept 29, 2026), average weight change was -17.6%, -23.7% and -25.0% across the three dose groups versus -3.9% on placebo, with reduced knee osteoarthritis pain and fewer sleep-apnea events in those subgroups. Source
  • human randomized trial (phase 3, topline)In the TRIUMPH-4 trial (obesity with knee osteoarthritis, 68 weeks), the top dose produced 28.7% average weight loss; dysesthesia (abnormal skin sensations) occurred in 20.9% at the top dose versus 0.7% on placebo, and 18.2% of that group stopped treatment because of adverse events, including some for perceived excessive weight loss. Source
  • human randomized trials (phase 3, topline)TRIUMPH-2 and TRIUMPH-3 (July 2026 topline) reported 12.7-22.6% weight loss over 80 weeks in people with type 2 diabetes or cardiovascular disease. Source

Human evidence: moderate. Large phase 2 and phase 3 randomized trials exist for obesity and related conditions, but the drug is still investigational and long-term safety is not yet established.

Tested lifters

Not named on the 2026 list. Sport Integrity Australia states GLP-1 agonists are not currently prohibited; some analysts argue that unapproved retatrutide could be caught by the S0 (non-approved substances) catch-all.

Unclear. Sources disagree because it is unapproved. A tested lifter should get a written answer from Global DRO or USADA first. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.

FDA status

Investigational, not FDA-approved. Lilly has said it plans to submit to FDA by Q1 2027 (per July 2026 reporting). Anything sold now as 'retatrutide' or 'LY3437943' outside a clinical trial is an unapproved product; FDA warning letters to online peptide sellers in August-September 2026 treated such products as unapproved new drugs.

As of 2026-10-01.

The approved cousins

Semaglutide. FDA-approved (Ozempic for type 2 diabetes; Wegovy for chronic weight management). FDA declared the semaglutide shortage resolved on Feb 21, 2025, ending broad shortage-based compounding. The Fifth Circuit upheld FDA's shortage removals for semaglutide and tirzepatide in 2026. A 2026 MRI sub-analysis of the STEP UP trial found semaglutide reduced fat and also skeletal muscle volume, while sit-to-stand performance was preserved.

Tirzepatide. FDA-approved (Mounjaro for type 2 diabetes; Zepbound for weight management and obstructive sleep apnea). It is a dual GIP/GLP-1 agonist and was also removed from FDA's shortage list.

WADA. Semaglutide and tirzepatide are not prohibited; markers are on the WADA Monitoring Program.

Known and theoretical risks

  • Dose-related gastrointestinal effects (nausea, diarrhea, vomiting, constipation) and dose-dependent heart-rate increases. Source
  • Dysesthesia (abnormal skin sensations) in about 1 in 5 people at the top dose in TRIUMPH-4, and treatment discontinuation linked to excessive weight loss. Source
  • Rapid weight loss on incretin drugs includes loss of lean and muscle tissue, a specific concern for strength athletes (shown for semaglutide in MRI data). Source
  • Gray-market 'research' products have no regulatory quality control; FDA has warned online sellers. Source

Quick answers

Is Retatrutide banned for drug-tested lifters?

Not named on the 2026 list. Sport Integrity Australia states GLP-1 agonists are not currently prohibited; some analysts argue that unapproved retatrutide could be caught by the S0 (non-approved substances) catch-all. Unclear. Sources disagree because it is unapproved. A tested lifter should get a written answer from Global DRO or USADA first. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.

Is Retatrutide FDA approved?

Investigational, not FDA-approved. Lilly has said it plans to submit to FDA by Q1 2027 (per July 2026 reporting). Anything sold now as 'retatrutide' or 'LY3437943' outside a clinical trial is an unapproved product; FDA warning letters to online peptide sellers in August-September 2026 treated such products as unapproved new drugs.

How strong is the human evidence for Retatrutide?

Moderate. Large phase 2 and phase 3 randomized trials exist for obesity and related conditions, but the drug is still investigational and long-term safety is not yet established.

Sources

Research-use-only information file. Nothing here is medical advice or instructions for use. Not evaluated by the FDA. Talk to your doctor.

More files

Back to the basement